Singh, Jasvinder A.
Cleveland, John D.
Funding for this research was provided by:
research funds from the Division of Rheumatology at the University of Alabama at Birmingham (No number)
the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA (No number)
Article History
Received: 21 March 2018
Revised: 15 April 2018
Accepted: 24 April 2018
First Online: 3 May 2018
Compliance with ethical standards
:
: There are no financial conflicts related directly to this study. JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center. JDC has no conflicts.
: The study was approved by the Institutional Review Board (IRB) at the University of Alabama at Birmingham (UAB).